04:20 AM EDT, 03/14/2025 (MT Newswires) -- Exicure ( XCUR ) said late Thursday it received a patent in Australia covering its combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.

The patent supports the company's ongoing phase 2 clinical trial assessing the combination of GPC-100 and propranolol to treat multiple myeloma, a cancer of plasma cells.